Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its financial results for the quarter- and year-ended December 31, 2017 and provided interim data from its Phase 2 trial of relacorilant to treat patients with hypercortisolism.

As quoted in the press release:

Operating expenses increased to $31.6 million in the fourth quarter 2017, from $18.8 million in the fourth quarter 2016, primarily due to increased spending to develop the company’s proprietary, selective cortisol modulators, including relacorilant, CORT125281 and CORT118335.  Costs resulting from revenue growth also increased, primarily compensation expense for the company’s expanded sales force and the cost of dispensing Korlym^® to more patients.

Click here to read the full press release.